PTCT FY2025 EPS Forecast Raised by Cantor Fitzgerald

PTC Therapeutics, Inc. (NASDAQ:PTCT) – Stock analysts at Cantor Fitzgerald boosted their FY2025 earnings per share (EPS) estimates for PTC Therapeutics in a research note issued to investors on Wednesday, November 5th. Cantor Fitzgerald analyst K. Kluska now anticipates that the biopharmaceutical company will post earnings per share of $9.04 for the year, up from their prior estimate of $7.49. Cantor Fitzgerald has a “Overweight” rating and a $118.00 price target on the stock. The consensus estimate for PTC Therapeutics’ current full-year earnings is ($4.52) per share. Cantor Fitzgerald also issued estimates for PTC Therapeutics’ FY2026 earnings at ($2.72) EPS.

Other equities research analysts have also issued research reports about the stock. Wells Fargo & Company raised their price target on shares of PTC Therapeutics from $73.00 to $93.00 and gave the stock an “overweight” rating in a research note on Wednesday. Jefferies Financial Group increased their price objective on PTC Therapeutics from $63.00 to $77.00 and gave the company a “buy” rating in a report on Tuesday, October 28th. Royal Bank Of Canada boosted their target price on PTC Therapeutics from $70.00 to $82.00 and gave the company an “outperform” rating in a research note on Wednesday. Cowen reaffirmed a “hold” rating on shares of PTC Therapeutics in a research report on Wednesday. Finally, Weiss Ratings reiterated a “hold (c-)” rating on shares of PTC Therapeutics in a research note on Wednesday, October 8th. Ten analysts have rated the stock with a Buy rating, six have assigned a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and an average target price of $75.40.

PTC Therapeutics Stock Performance

NASDAQ PTCT opened at $72.59 on Friday. The company has a market capitalization of $5.77 billion, a PE ratio of 10.41 and a beta of 0.60. PTC Therapeutics has a 52-week low of $35.95 and a 52-week high of $73.98. The company has a 50-day simple moving average of $62.86 and a 200 day simple moving average of $53.44.

PTC Therapeutics (NASDAQ:PTCT) last announced its earnings results on Tuesday, November 4th. The biopharmaceutical company reported $0.20 earnings per share (EPS) for the quarter, beating the consensus estimate of ($1.19) by $1.39. The firm had revenue of $211.01 million during the quarter, compared to analyst estimates of $177.42 million. PTC Therapeutics had a negative return on equity of 106.31% and a net margin of 35.65%.The business’s revenue was up 7.2% compared to the same quarter last year. During the same period last year, the firm posted ($1.39) EPS. PTC Therapeutics has set its FY 2025 guidance at EPS.

Insider Buying and Selling

In other PTC Therapeutics news, insider Eric Pauwels sold 39,850 shares of PTC Therapeutics stock in a transaction dated Monday, September 8th. The stock was sold at an average price of $56.92, for a total transaction of $2,268,262.00. Following the completion of the transaction, the insider owned 72,912 shares of the company’s stock, valued at $4,150,151.04. The trade was a 35.34% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. Also, insider Neil Gregory Almstead sold 55,000 shares of the company’s stock in a transaction dated Friday, October 3rd. The shares were sold at an average price of $66.05, for a total value of $3,632,750.00. Following the sale, the insider owned 100,625 shares in the company, valued at approximately $6,646,281.25. This represents a 35.34% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Insiders sold 254,662 shares of company stock valued at $16,000,821 in the last 90 days. Corporate insiders own 5.50% of the company’s stock.

Institutional Trading of PTC Therapeutics

Several institutional investors and hedge funds have recently bought and sold shares of the company. Nuveen LLC bought a new position in PTC Therapeutics in the 1st quarter valued at $51,427,000. Wellington Management Group LLP boosted its stake in PTC Therapeutics by 13.2% during the first quarter. Wellington Management Group LLP now owns 5,419,172 shares of the biopharmaceutical company’s stock valued at $276,161,000 after buying an additional 632,049 shares during the period. Hood River Capital Management LLC grew its position in PTC Therapeutics by 654.4% during the second quarter. Hood River Capital Management LLC now owns 636,502 shares of the biopharmaceutical company’s stock worth $31,087,000 after buying an additional 552,130 shares in the last quarter. State Street Corp increased its stake in PTC Therapeutics by 22.1% in the 2nd quarter. State Street Corp now owns 2,996,454 shares of the biopharmaceutical company’s stock worth $146,347,000 after acquiring an additional 541,558 shares during the last quarter. Finally, Driehaus Capital Management LLC raised its holdings in shares of PTC Therapeutics by 45.3% in the 1st quarter. Driehaus Capital Management LLC now owns 1,512,645 shares of the biopharmaceutical company’s stock valued at $77,084,000 after acquiring an additional 471,586 shares in the last quarter.

PTC Therapeutics Company Profile

PTC Therapeutics, Inc, a biopharmaceutical company, focuses on the discovery, development, and commercialization of medicines to patients with rare disorders in the United States and internationally. The company offers Translarna and Emflaza for the treatment of Duchenne muscular dystrophy; Upstaza to treat aromatic l-amino acid decarboxylas (AADC) deficiency, a central nervous system disorder; Tegsedi and Waylivra for the treatment of rare diseases; and Evrysdi to treat spinal muscular atrophy (SMA) in adults and children.